Document:

exv10w2

Exhibit 10.2

FORM OF VOTING COMMON STOCK PURCHASE WARRANT

NEITHER THIS WARRANT NOR ANY SHARES ACQUIRED UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) OR UNDER ANY STATE SECURITIES LAWS. NEITHER THIS
WARRANT NOR ANY SUCH SHARES MAY BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND STATE SECURITIES LAWS OR THE AVAILABILITY
OF AN EXEMPTION FROM SUCH REGISTRATION.

For the Purchase of _______ Shares

AXCESS INTERNATIONAL, INC.

Voting Common Stock Purchase Warrant

The following recitals are true and constitute the basis for this Warrant:

	A.	 	This Warrant is issued to Amphion Innovations plc or their successors in interest, assigns or
transferees (collectively, the “Warrant Holder”), in consideration for the Convertible Note
issued October 28, 2009 by Axcess International, Inc., a Delaware corporation (the
“Company”).;
	 
	B.	 	The total number of shares of the Company’s Voting Common Stock (as defined in Section 9(a)
hereof) (the “Warrant Shares”)
to be issued to the Warrant Holder is                                          shares (*** ___***); and
	 
	C.	 	This Warrant shall be exercisable at any time and from time to time on or prior to the
December 31, 2014.

     THIS CERTIFIES THAT, for value received, the Warrant Holder is entitled to purchase from the
Company, ___ Warrant Shares at the exercise price of No Dollars and Seventy-Five Cents ($0.75)
per share (the “Exercise Price”).

     Section 1. Exercise of Warrant.

     The rights represented by this Warrant may be exercised by the Warrant Holder, in whole or in
part, by delivering to the Company a duly executed notice of exercise in the form of ANNEX
A hereto and delivering a check payable to (or wire transfer to the account of) the Company in
an amount equal to the product of (x) the Exercise Price times (y) the number of Warrant Shares as
to which this Warrant is being exercised (such product, the “Total Exercise Price”). This Warrant
shall be deemed to have been exercised immediately prior to the close of business on the date of
delivery of a duly executed notice of exercise together with the amount (in cash) payable upon
exercise of this Warrant and, as of such moment, (i) the rights of the Warrant Holder, as such,
with respect to the number of Warrant Shares as to which this Warrant is being exercised shall
cease, and (ii) such Warrant Holder shall be deemed to be the record holder of the shares of Voting
Common Stock issuable upon such exercise. As soon as practicable after the exercise, in whole or in
part, of this Warrant, and in any event within 10 business days thereafter, the Company at its
expense (including the payment by it of any applicable issuance or stamp taxes) will cause to be
issued in the name of and delivered to the Warrant Holder, or as the Warrant Holder (upon payment
by the Warrant Holder of any applicable transfer taxes) may direct, a certificate or certificates
for the number of fully paid and nonassessable shares of Voting Common Stock to which the Warrant
Holder shall be entitled upon such exercise. In the event of partial exercise of this Warrant, the
Warrant need not be delivered to the Company; provided that the Warrant Holder agrees to make a
notation of such partial exercise and, if applicable, surrender on the Warrant. If this Warrant is
delivered to the Company, the Company shall issue and deliver to the Warrant Holder a new Warrant
evidencing the rights to purchase the remaining Warrant Shares, which new Warrant shall in all
other respects be identical to this Warrant.

 

 

      Section 2. Investment Representation.

     By accepting this Warrant, the Warrant Holder represents that the Warrant Holder is acquiring
this Warrant for investment purposes and will not sell or otherwise dispose of this Warrant or the
underlying Warrant Shares in violation of applicable securities laws. The Warrant Holder
acknowledges that the certificates representing any Warrant Shares will bear a legend indicating
that they have not been registered under the Act, and may not be sold by the Warrant Holder except
pursuant to an effective registration statement or pursuant to an exemption from registration.

      Section 3. Validity of Warrant and Issue of Shares.

     The Company represents and warrants that this Warrant has been duly authorized and validly
issued and covenants and agrees that all shares of Common Stock that may be issued upon the
exercise of the rights represented by this Warrant will, when issued upon such exercise, be duly
authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges
with respect to the issue thereof. The Company further covenants and agrees that during the period
within which the rights represented by this Warrant may be exercised, the Company will at all times
have authorized and reserved a sufficient number of shares of Common Stock to provide for the
exercise of the rights represented by this Warrant.

     The Company shall not be required upon the exercise of this Warrant to issue any fraction of
shares, but shall make any adjustment therefore by rounding the number of shares obtainable upon
exercise to the next highest whole number of shares.

      Section 4. Transfer of Rights.

     This Warrant is transferable in whole or in part, at the option of the Warrant Holder, upon
delivery of a duly executed Warrant Assignment Form in the form annexed as ANNEX B hereto.
The Company shall execute and deliver a new Warrant or Warrants in the form of this Warrant with
appropriate changes to reflect the issuance of subsequent Warrants in the name of the assignee or
assignees named in such instrument of assignment, and if the Warrant Holder’s entire interest is
not being transferred or assigned, in the name of the Warrant Holder, and this Warrant shall
promptly be canceled. Any transfer or exchange of this Warrant shall be without charge to the
Warrant Holder, and any new Warrant or Warrants issued shall be dated the date hereof. The term
"Warrant” as used herein includes any Warrants into which this Warrant may be divided or for which
it may be exchanged. The Warrant Holder (and not the Company) will be responsible for any stamp,
transfer or other taxes payable on any such transfer.

      Section 5. Lost, Mutilated or Missing Warrant.

     Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or
mutilation of this Warrant, and upon surrender and cancellation of this Warrant, if mutilated, the
Company shall execute and deliver a new Warrant of like denomination and date.

      Section 6. Rights of Warrant Holder.

     The Warrant Holder shall not, by virtue hereof, be entitled to any voting or other rights of a
shareholder of the Company, either at law or equity, and the rights of the Warrant Holder are
limited to those expressed in this Warrant.

      Section 7. Successors.

     All the provisions of this Warrant by or for the benefit of the Company or the Warrant Holder
shall bind and inure to the benefit of their respective successors and assigns.

      Section 8. Miscellaneous.

     (a) This Warrant shall be construed in accordance with and governed by the laws of the State
of Delaware.

 

 

     (b) The caption headings used in this Warrant are for convenience of reference only and shall
not be construed in any way to affect the interpretation of any provisions of this Warrant.

      Section 9. Notices.

     Any notice pursuant to this Warrant shall be effective if sent by first class mail, postage
prepaid, or delivered by facsimile transmission, addressed as follows:

     If to the Company, then to it at:

Axcess International Inc.

3208 Commander Drive

Dallas, Texas 75006

Attention: Chief Financial Officer

Facsimile No.: (972) 407-9085

     (or to such other address as the Company may have furnished in writing to the Warrant Holder
for this purpose); and

     If to the Warrant Holder, then to it at such address as such Warrant Holder may have furnished
in writing to the Company for this purpose.

     IN WITNESS WHEREOF, the Company, intending to be legally bound hereby, has caused this Warrant
to be signed by its President and Chief Executive Officer and attested by its Secretary or
Assistant Secretary as of the date set forth below.

	 	 	 	 	 
	 	AXCESS INTERNATIONAL INC.

 	 
	 	By:  	/s/ Allan Frank
 	 
	 	 	Allan Frank, Chief Financial Officerexv10w1

EXHIBIT 10.1

PRODUCT COMMERCIALIZATION AGREEMENT

     This Product Commercialization Agreement (this “Agreement”) is entered into by and between
Mylan Pharmaceuticals Inc. (“Mylan”), a West Virginia corporation having its corporate offices at
781 Chestnut Ridge, Morgantown, West Virginia, 26505 and Dow Pharmaceutical Sciences, Inc.
(“DPSI”), a Delaware corporation having its corporate offices at 1330 Redwood Way, Petaluma,
California, 94954-1169.

     WHEREAS, DPSI has developed the Product and has filed an ANDA with the FDA to obtain approval
for the manufacture, distribution and sale of the Product in the Territory; and

     WHEREAS, DPSI wishes to appoint Mylan as its distributor of the Product in the Territory
during the Term of this Agreement, all upon the terms and subject to the conditions set forth in
this Agreement.

     NOW THEREFORE, intending to be legally bound and in consideration of the mutual promises,
covenants and conditions set forth herein, and for other good and valuable consideration the
receipt and sufficiency of which is hereby acknowledged, Mylan and DPSI agree as follows:

ARTICLE 1 DEFINITIONS

     1.1 “Adverse Drug Experience” shall mean an adverse event associated with the use of the
Product in humans, whether or not considered drug related, including the following: an adverse
event occurring in the course of the use of a drug product in professional practice; an adverse
event occurring from drug overdose whether accidental or intentional; an adverse event occurring
from drug abuse; an adverse event occurring from drug withdrawal; and any failure of expected
pharmacological action. The above definition of “Adverse Drug Experience” is defined by 21 C.F.R.
§ 314.80(a) and will be deemed to be changed to reflect any changes to that section of the
U.S. Code of Federal Regulations.

     1.2 “Affiliate” shall mean any corporation, association, partnership, company, organization,
joint venture, or other entity which directly or indirectly controls, is controlled by, or is under
common control with Mylan or DPSI as the case may be. For purposes of this definition, control
means the ability, directly or indirectly, through ownership of securities or other equity
interests, by agreement, or by any other lawful method, to direct more than fifty percent (50%) of
the outstanding equity votes of any entity, whether or not represented by securities, or to
otherwise control the management and policy decisions of any entity.

     1.3 “Agreement” shall mean this Product Commercialization Agreement.

     1.4 “ANDA” shall mean an Abbreviated New Drug Application within the meaning of Section 505(j)
of the U.S. Food, Drug and Cosmetic Act.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

 

 

     1.5 “Commercially Reasonable Efforts” shall mean that degree of effort, expertise and
resources which a person of ordinary skill, ability and experience in the matters addressed in this
Agreement would utilize and otherwise apply with respect to fulfilling the obligations assumed
under this Agreement.

     1.6 “Cost of Goods” shall mean DPSI’s and Mylan’s (once Mylan, or a Mylan Affiliate, begins
manufacturing the Product in accordance with this Agreement) direct costs (including out-of-pocket
costs and directly allocable internal manufacturing overheads) of manufacture, testing, validation
and shipping of the Product to Mylan’s facilities, including DPSI’s and Mylan’s acquisition and
shipping costs of API. Also, Cost of Goods shall include all labeling and packaging of components
by Mylan. [**] When, and if applicable, the Cost of Goods shall be calculated and accrued in
accordance with U.S. Generally Accepted Accounting Principles. Cost of Goods shall not include any
allocation for idle plant or corporate overheads.

     1.7 “Commencement of Commercial Sales” shall mean the first arms — length commercial sale of
the Product by Mylan, its Affiliates, agents, or distributors to a Third Party.

     1.8 [**]

     1.9 “[**] Patents” shall mean U.S. patents [**] or [**] and/or any continuation,
continuation-in-part, division or re-issue of either of them.

     1.10 [**]

     1.11 “DPSI” shall mean Dow Pharmaceutical Sciences, Inc.

     1.12 “Effective Date” shall mean February 21, 2008.

     1.13 “FDA” shall mean the United States Food and Drug Administration.

     1.14 “Force Majeure” shall mean any circumstances reasonably beyond a Party’s control
including, without limitation, acts of God, civil disorders or commotions, acts of aggression,
fire, explosions, floods, drought, war, sabotage, embargo, utility failures, failure of supply of
Product to Mylan, failure to secure a supply agreement as required by Section 5.1, material
shortages, labor disturbances, strikes, a national emergency or appropriations of property and
which occurrence prevents a Party from performing its obligations under this Agreement.

     1.15 “Indemnified Party” shall have the meaning ascribed to it in Section 10.4.

     1.16 “Indemnifying Party” shall have the meaning ascribed to it in Section 10.4.

     1.17 “JDC” shall mean the Joint Development Committee described in Section 2.2.

     1.18 “Law” shall mean any rule, regulation, statute, ordinance or other rule of law relevant
to the manufacture, distribution and/or sale of any or all of the Product, or to any other matters
covered by this Agreement.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

2

 

     1.19 “Legal Expenses” shall mean the costs incurred by either Mylan or DPSI, or both of them,
in connection with the defense of any claims asserted by a Third Party alleging infringement of
such Third Party’s intellectual property rights during the Term of this Agreement, including but
not limited to counsel fees, court costs, expert witness fees, translation expenses and other
necessary litigation expenses.

     1.20 “Losses” shall mean liabilities, damages, costs or expenses, including reasonable
attorneys’ fees, incurred by either Party which arises from any claim, lawsuit or other action by a
Third Party.

     1.21 “Mylan” shall mean Mylan Pharmaceuticals Inc.

     1.22 “Net Profits” shall mean, for any period of determination, an amount equal to Net Sales
during that period less the Cost of Goods of the Product.

     1.23 “Net Sales” shall mean, for any period of calculation, the aggregate gross amount
invoiced by Mylan to its customers during that period for commercial sales of the Product, less:

          (a) Discounts, rebates, chargebacks, adjustments (including retroactive or shelf stock
adjustments), cash incentive payments or any other discounts as may be accrued or actually paid,
credited or given by Mylan to customers in connection with the sale of Product;

          (b) Excise, sales and other taxes imposed upon the sale of Product (but not taxes imposed on
the income generated from such sales);

          (c) Amounts repaid or credited by reason of rejection or returns (including by reason of
customer disputed quantities, shortages, damaged Product, or unsold or expired Product three (3)
months beyond its “Sell By” date);

          (d) All discounts, rebates, or other payments required by Law to be made under U.S. Medicaid,
Medicare or any other governmental special medical assistance program; and

          (e) Appropriate deductions for bad debts and uncollectible accounts for the applicable
accounting Period.

     1.24 “Party” shall mean Mylan or DPSI and “Parties” shall mean Mylan and DPSI.

     1.25 “Period” shall mean a calendar year beginning on the Commencement of Commercial Sales and
ending on December 31st and each calendar year thereafter during the Term of this
Agreement (as defined below).

     1.26 “Product” shall mean Benzoyl Peroxide / Clindamycin topical gel, equivalent to
Benzaclin® topical gel (clindamycin [1%] as clindamycin phosphate, benzoyl peroxide [5%])
packaged in 50 gram jars.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

3

 

     1.27 “Quarter Date” shall mean any one of 30 September, 31 December, 31 March or 30 June.

     1.28 “Quarter” means each period of three (3) consecutive months during the term of this
Agreement ending on a Quarter Date provided that:

          (a) The period from the Commencement of Commercial Sales until the first Quarter Date
thereafter is deemed to be a Quarter; and

          (b) The period from the last Quarter Date prior to termination, through the termination date,
of this Agreement is deemed to be a Quarter.

     1.29 “Territory” shall mean the United States of America and its territorial possessions and
protectorates, including the District of Columbia, Puerto Rico, the U.S. Virgin Islands, the
Marshall Islands and Guam.

     1.30 “Term of this Agreement” shall have the meaning ascribed to it in Section 12.1.

     1.31 “Third Party” shall mean any entity or person other than Mylan or DPSI or their
respective Affiliates.

ARTICLE 2 PRODUCT DEVELOPMENT

     2.1 ANDA. DPSI will prosecute the ANDA for the Product and take all actions necessary to
obtain full and effective FDA approval as expeditiously as possible for the manufacture,
distribution and sale of the Product in the Territory. If DPSI fails or is unable or unwilling to
take any action necessary in relation to the preparation, filing, prosecution or maintenance of the
ANDA for the Product, then Mylan, either itself or through agents or designees, shall be authorized
to take all necessary and reasonable steps in connection with such filings at DPSI’s expense, such
expense to be authorized in advance by DPSI, including without limitation, to file or have filed
supplements or amendments to the ANDA and to respond to and correspond with the FDA as necessary in
connection therewith, and DPSI shall execute such powers of attorney, consents, assignments or
other instruments as may be required for Mylan to perform such activities.

     2.2 Joint Development Committee. Mylan and DPSI shall establish a Joint Development Committee
(“JDC”) which shall monitor the progress of the ANDA toward final approval and the other Product
development and regulatory activities DPSI is to perform under this Agreement, and to act in an
advisory capacity to the Parties in relation to such matters. The JDC shall establish a timetable
for completion of the Product development and regulatory activities contemplated hereunder and also
recommend what further development and regulatory activities are required in order to attain full
and effective final approval from FDA for the Product in the Territory. The JDC shall be comprised
of three (3) representatives appointed by DPSI and three (3) representatives appointed by Mylan.
Meetings of the JDC may be convened upon reasonable notice to both Parties and may be conducted
either in person or telephonically or by videoconference. In accordance with Section 8.2, the JDC
shall meet quarterly to discuss

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

4

 

and agree on Product pricing strategy. The meetings and recommendations of the JDC shall be
recorded and reflected in minutes of the JDC’s meetings which shall be reviewed and formally
approved by the JDC.

ARTICLE 3 PAYMENTS AND COSTS

     3.1 Initial Payment. In consideration of the appointment of Mylan as DPSI’s exclusive
distributor of the Product in the Territory, Mylan will pay to DPSI a one-time, nonrefundable
payment of [**] U.S. DOLLARS (U.S. $[**]) as follows (singularly and collectively “Initial
Payment”):

          (a) [**] U.S. DOLLARS ($[**] USD) upon both Parties signing this Agreement; and

          (b) [**] U.S. DOLLARS ($[**] USD) within forty five (45) calendar days after: [**].

          3.1.1 If the payment of the Initial Payment is not received by DPSI in terms of Section 3.1
(a) and (b), this Agreement shall automatically terminate without further notice from DPSI.

          3.1.2 Mylan agrees that upon payment to DPSI, the Initial Payment paid in accordance Section
3.1 (a) and (b) above is not refundable (either in whole or in part) and is not creditable (either
in whole or in part) against any other payments made or to be made by Mylan to DPSI under this
Agreement.

     3.2 Development Costs. [**] will bear and pay the costs and expenses of all Product
development work conducted pursuant to this Agreement to facilitate regulatory approval for the
Product. [**] will bear and pay the costs and expenses of all costs associated with commercial
distribution of the Product.

     3.3 Legal Expenses. If Mylan or DPSI or either of them is sued for patent infringement in
connection with the filing of the ANDA for the Product, or in connection with the manufacture, use,
distribution or sale of the Product in the Territory during the Term of this Agreement, then Mylan
shall have the right at its option to control the defense of such litigation, and to select and
direct counsel. Mylan will consult with DPSI in regards to the defense of all such matters. [**]
will [**] all Legal Expenses incurred during the Term of this Agreement relating to Third Party
claims alleging patent infringement or other infringement of Third Party intellectual property
rights [**], regardless of which Party actually pays or incurs such Legal Expenses. DPSI will
reasonably cooperate in the defense of any litigation relating to the Product, including without
limitation making its employees available for interviews, meetings, discovery proceedings and
trial, answering discovery requests and producing documents and things as may be necessary.
Neither DPSI nor Mylan will enter into any settlement of any litigation or other dispute or claim,
or any agreement with any Third Party, the effect of which could be to delay the market launch date
of the Product or otherwise impair or diminish the economic value of the Product opportunity
without prior notice and consultation with the other

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

5

 

Party and without the other Party’s express written consent, not to be unreasonably withheld.
For avoidance of doubt, the provisions in this Section relating to the sharing of Legal Expenses
shall relate solely to Third Party claims alleging infringement of any Third Party’s intellectual
property rights.

ARTICLE 4 EXCLUSIVITY

     4.1 Exclusive Development. During the Term of this Agreement, DPSI will develop the Product
for Mylan, and [**] shall supply the Product to Mylan as set forth in Section 5.1 (unless Mylan
manufactures the Product as set forth in Section 5.2), for sale in the Territory, on an exclusive
basis. DPSI will not prepare or file any application seeking approval to commercialize the Product
in the Territory other than for Mylan in accordance with this Agreement.

     4.2 Semi-Exclusive Distribution. Mylan’s commercial distribution rights with respect to the
Product within the Territory shall be exclusive. Notwithstanding the foregoing, DPSI and/or any of
its Affiliates may, in DPSI’ s discretion, itself and not through any Third Party, commercialize a
DPSI-branded version of the Product under a DPSI trade name and trade dress and NDC number, subject
to DPSI’s payment to Mylan of [**] of gross margin received by DPSI as would have been generated by
Mylan under agreed terms of sale of the Product and as derived from all Product sale by DPSI of the
DPSI-branded version of the Product in the Territory under this Agreement.

     4.3 No Sales Outside the Territory. During the Term of this Agreement, Mylan shall not
promote or distribute the Product outside the Territory, nor shall Mylan sell such Product to any
purchaser that Mylan knows, or reasonably ought to know, intends to resell or redistribute the
Product outside the Territory. For avoidance of doubt, nothing in this Agreement shall preclude or
limit Mylan or its Affiliates from marketing, promoting, manufacturing, purchasing, distributing,
or selling Third Party drug products that contain the same active ingredients as the Product
outside the Territory; provided, Mylan notifies DPSI of its intention to do so thirty (30) days
prior commencement of such Third Party drug sales outside the Territory.

     4.4 [**]

ARTICLE 5 SUPPLY AGREEMENT AND MANUFACTURING RIGHTS

     5.1 Supply Agreement with [**]. Mylan, DPSI and [**] shall enter into a mutually satisfactory
agreement pursuant to which Mylan is assured supply of the Product throughout the Term of this
Agreement.

     5.2 Mylan Manufacturing Rights. Mylan and its Affiliates shall have the right to manufacture
the Product either in or outside the Territory and DPSI shall provide all necessary consents,
assignments and reasonable regulatory and technical assistance as may be reasonably necessary in
order to effectuate the change in the site of manufacture of the Product.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

6

 

ARTICLE 6 REGULATORY RESPONSIBILITIES

     6.1 ANDA Holder’s Responsibilities. As the holder of the ANDAs, DPSI will have sole authority
to deal with regulatory matters relating to the Product except as otherwise specifically stated in
this Agreement. During the Term of this Agreement, DPSI shall pay all associated fees and maintain
all ANDAs for the Product in accordance with applicable Law and requirements of the FDA, including
the filing of all annual and other reports or filings required by the FDA, and all other regulatory
and governmental permits, licenses and approvals for the Product that are necessary for DPSI to
manufacture, package, test, label, handle and ship the Product to Mylan and its Affiliates in
accordance with the terms of this Agreement and applicable Law.

     6.2 NDC Codes. Mylan shall obtain its own labeler code, drug listing and NDC for use in
connection with the sale of Product pursuant to the terms and conditions of this Agreement, and
will promptly provide such information to DPSI as needed for inclusion on the label of Product
supplied to Mylan pursuant to this Agreement.

     6.3 Adverse Drug Experiences. Mylan will submit to DPSI all reports of Adverse Drug
Experiences reported to Mylan, together with all relevant information possessed by Mylan, in a
format to facilitate direct submission to the FDA and in accordance with applicable CFR that are
from time to time in effect so as to allow DPSI to meet all periodic and annual safety and
regulatory obligations to the FDA. Mylan shall also promptly submit to DPSI all Product complaints
for investigation and feedback to DPSI. Each Party shall cooperate with the other and provide
information in its possession to the extent necessary for the other Party to comply with all legal
requirements relating to the manufacture or marketing of the Product in the Territory. The Parties
will use Commercially Reasonable Efforts to agree upon a customary pharmacovigilance protocol as
promptly as practicable after the Effective Date to provide for the necessary exchange of adverse
event and related information. DPSI and Mylan will cooperate in good faith in establishing a
mechanism, for timely customer responses to inquiries of a medical or technical nature with respect
to the Product.

     6.4 Recalls. Mylan and DPSI will immediately inform the other in writing if it believes one
or more lots of any Product may be subject to recall from distribution, and will confer on the
reasons for such belief. To the extent permitted by Law and public safety, the Parties will confer
before initiating any Product recall. If the Parties do not reach agreement on the need for
Product recall, either Party may initiate a Product recall. The Party initiating the recall shall
initially bear the cost thereof and shall carry out the recall in accordance with best industry
practices. In the event it is determined that a recall resulted from a breach by any Party of any
of its representations or warranties under this Agreement, such Party shall be responsible for the
costs of the recall. The cost of any unnecessary or groundless recall shall be borne by the Party
initiating or requesting such recall. Except as otherwise provided above, the cost of any Product
recall based on, resulting from, or arising in connection with any labeling issue, a failure to
warn issue or a defect design issue shall be borne by DPSI.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

7

 

     6.5 Retention of Samples. DPSI shall keep such samples and records in respect of the Product
as are required by applicable Law for such period of time as may be required by Law.

     6.6 FDA Correspondence. Each of Mylan and DPSI shall promptly inform the other of any
correspondence from the FDA regarding the Product that would materially affect its ability to meet
its obligations under this Agreement. Each of Mylan and DPSI shall notify the other promptly of
any materially adverse inspections by the FDA or other regulatory authorities which pertain to the
Product or to the facilities of such Party or its Affiliate where the Product is being manufactured
or stored, or any occurrences or information that arise out of DPSI’s or Mylan’s manufacturing
activities that could have reasonably been expected to have adverse regulatory compliance or
reporting consequences concerning any Product or which might otherwise be reasonably expected to
adversely affect the supply by DPSI of the Product to Mylan. Mylan agrees that DPSI shall be
solely responsible for responding to any correspondence from the FDA relating to the Product and
shall be the sole point of contact with the FDA regarding the Product. DPSI will give Mylan thirty
(30) days (or such other amount of time as may be imposed on DPSI) to review and comment on any
proposed communications with the Office of Generic Drugs of the FDA that in DPSI’s opinion
materially affect (excluding periodic and routine reports) the Product and shall take Mylan’s
comments which are received within the required time, if any, into account in communicating with
FDA.

     6.7 Quality and PV Agreement. Within ninety (90) days following mutual signature of this
Agreement, the Parties shall enter into a Quality and Pharmacovigilance Agreement (which may be two
separate contracts) in form and content reasonably acceptable to the Parties and containing
protocols and specific responsibilities for handling Product quality complaints, Adverse Drug
Experience reports, and professional medical service inquiries in accordance with Mylan’s and/or
DPSI’s standard operating procedures and in conformity with FDA requirements and applicable Law.
Mylan will bear the responsibility of the Pharmacovigilance Agreement at its cost and make the
information available to DPSI to meet the regulatory requirements.

ARTICLE 7 PROFIT SHARING

     7.1 Profit Sharing.

          7.1.1 Mylan shall pay DPSI [**] percent ([**]%) of Mylan’s Net Profits derived from sales of
Product in the Territory.

          7.1.2 For the first fiscal year Quarter in which the Commencement of Commercial Sale of the
Product occurs, and for in that Quarter only, the profit share will be paid by Mylan on a Quarterly
basis. Subsequent to such Quarter, the profit sharing payments will be calculated and paid to DPSI
on a monthly basis. A monthly report of gross sales will be provided within ten (10) days of the
end of each month. A monthly report of Net Sales, Net Profit and DPSI’s profit share will be
generated within forty five (45) days of the end of each month, together with a report detailing
the calculations.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

8

 

          7.1.3 All payments will be made within forty five (45) days of the end of each month (except
for the first payment which will be due forty five (45) days after the first Quarter).

          7.1.4 If Net Sales of the Product in the Territory generate in excess of [**] US Dollars
($[**] USD) in Net Profit in a Period, then DPSI will be paid an additional [**] percent ([**]%)
share (for a total of [**] percent ([**]%)) of the incremental Net Profit above [**] US dollars
($[**] USD). For any Period which is less than twelve (12) months, Net Sales and Net Profit shall
be prorated accordingly.

          7.1.5 If Net Sales of the Product in the Territory generate in excess of [**] US Dollars
($[**] USD) in Net Profit in a Period, DPSI will be paid an additional [**] percent ([**]%) share
(for a total of [**] percent ([**]%)) of the incremental Net Profit above [**] US dollars ($[**]
USD). For any Period which is less than twelve (12) months, Net Sales and Net Profit shall be
prorated accordingly.

     7.2 Recordkeeping. During the Term of this Agreement and for one (1) year thereafter, or for
such longer period as may be required by Law, both DPSI and Mylan shall prepare and retain accurate
books and records as are needed to determine Cost of Goods, Net Sales and Net Profit. Such records
shall be made available for reasonable review, audit and inspection upon reasonable notice and with
reasonable frequency, upon the other Party’s request for the purpose of verifying the other Party’s
calculations, payments made and due, and the basis for such calculations or payments. Audits and
inspections may be conducted by a Party’s own personnel and/or retained consultant(s) who agree to
be bound by a reasonable confidentiality agreement.

ARTICLE 8 PRODUCT DISTRIBUTION

     8.1 Promotion of the Product. During the Term of this Agreement, Mylan shall use Commercially
Reasonable Efforts to promote the Product in the Territory; provided, however, that Mylan shall not
be deemed to have failed to abide by or have failed to perform in accordance with the foregoing
standard if Mylan is prevented from performing or is hindered in its performance by any act or
omission of DPSI or by Force Majeure.

     8.2 Launch Decisions, Timing and Pricing of Product. Prior to the Commencement of Commercial
Sale of the Product in the Territory by Mylan, and to the extent permitted by Law, Mylan and DPSI
shall discuss in good faith and endeavor to agree upon specific launch and pricing plans for the
Product, including the following: Product launch price; Product pricing and plans that will be
effective upon entry of the first generic competitor to the Product and subsequent generic
competitors; annual Product price strategy/actions; and inclusion of the Product in other Mylan
group product pricing arrangements. If the Parties should after good faith negotiations have
failed to agree on any the foregoing matters, such matters shall be referred to the President of
Mylan and the Chief Executive Officer of DPSI for a final decision.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

9

 

ARTICLE 9 OWNERSHIP OF APPLICATIONS AND INTELLECTUAL PROPERTY

     9.1 Ownership of ANDA. DPSI shall own and maintain at its own cost all ANDAs and associated
regulatory filings made for the Product.

     9.2 Ownership of Inventions and Know-How. DPSI shall own all inventions and know-how made by
DPSI in connection with the development of the Product under this Agreement, and shall have the
sole right to apply for and prosecute in its own name applications for any appropriate patents,
registrations, or other intellectual property protection for any and all such inventions. Mylan
shall own all inventions and know-how made by Mylan or its Affiliates in connection with the
Product, and shall have the sole right to apply for and prosecute in its own name applications for
any appropriate patents, registrations, or other intellectual property protection for any and all
such inventions. During the term of this Agreement, both Parties grant to one another a fully
paid-up royalty-free, non-revocable, world-wide license to the intellectual property owned by each
Party to the extent necessary to perform each Party’s duties and to exercise each Party’s rights
under this Agreement.

ARTICLE 10 INSURANCE AND INDEMNIFICATION

     10.1 Product Liability Insurance. Each Party shall, during the Term of this Agreement and for
two (2) years after termination or expiration of this Agreement, obtain and maintain at its own
cost and expense from a qualified insurance company (provided however that Mylan may be self
insured for such amounts through one or more Affiliates), comprehensive general liability insurance
and product liability insurance providing protection against any and all claims, demands, and
causes of action arising out of any defects, alleged or otherwise, of the Product or its use,
design, labeling or manufacture, or any material incorporated in the Product. The amount of
coverage shall be a minimum of ten million US dollars ($10,000,000 USD) combined single limit
coverage for each occurrence for bodily injury and/or for property damage. Each Party agrees, upon
request, to name the other Party as an additional insured on such policy and to furnish the other
Party with a certificate of insurance evidencing such insurance coverage, and the insured Party
shall not at any time act pursuant to this Agreement unless such insurance is in effect.

     10.2 Indemnity by DPSI. DPSI agrees to indemnify, defend and hold harmless Mylan and its
Affiliates and their respective directors, officers, employees, consultants, representatives and
agents from and against any and all Losses relating to (i) any material breach by DPSI of its
representations, covenants or warranties in this Agreement, and (ii) any negligence or willful
misconduct of DPSI or its Affiliates and their respective directors, officers, employees,
consultants, representatives and agents, in the exercise of any of DPSI’s rights or the performance
of any of DPSI’s obligations under this Agreement.

     10.3 Indemnity by Mylan. Mylan agrees to indemnify, defend and hold harmless DPSI and its
Affiliates and their respective directors, officers, employees, consultants, representatives and
agents from and against any and all Losses relating to (i) any material breach by Mylan of its
representations, covenants or warranties in this Agreement, and (ii) any negligence or willful
misconduct of Mylan or its Affiliates and their respective directors,

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

10

 

officers, employees, consultants, representatives and agents, in the exercise of any of
Mylan’s rights or the performance of any of Mylan’s obligations under this Agreement.

     10.4 Procedure. A Party seeking indemnification under this Agreement (“Indemnified Party”)
shall promptly notify, in writing, the other Party (“Indemnifying Party”) of the assertion of any
claim or discovery of any fact upon which the Indemnified Party intends to base a claim for
indemnification. An Indemnified Party’s failure to so notify the Indemnifying Party shall not,
however, relieve such Indemnifying Party from any liability under this Agreement to the Indemnified
Party with respect to such claim except to the extent that such Indemnifying Party is actually
denied, during the period of delay in notice, the opportunity to remedy or otherwise mitigate the
event or activity(ies) giving rise to the claim for indemnification and thereby suffers or
otherwise incurs additional Losses as a result of such failure. The Indemnifying Party, while
reserving the right to contest its obligations to indemnify, shall be responsible for the defense
of any claim, demand, lawsuit or other proceeding in connection with which the Indemnified Party
claims indemnification. The Indemnified Party shall have the right at its own expense to
participate jointly with the Indemnifying Party in the defense of any such claim, demand, lawsuit
or other proceeding, but with respect to any issue involved in such claim, demand, lawsuit or other
proceeding with respect to which the Indemnifying Party has acknowledged its obligation to
indemnify the Indemnified Party, the Indemnifying Party shall have the right to select counsel,
settle, try or otherwise dispose of or handle such claim, demand, lawsuit or other proceeding on
such terms as the Indemnifying Party shall deem appropriate, subject to any reasonable objection of
the Indemnified Party. An Indemnifying Party’s right to control, select counsel for, settle,
defend, try or otherwise dispose of or handle a claim, demand, lawsuit or other proceeding, does
not give the Indemnifying Party the right: (i) to admit wrongdoing of any kind by or on behalf of
the Indemnified Party; (ii) to falsely disparage the reputation of the Indemnified Party; (iii) to
cause the Indemnified Party to be debarred; or (iv) to agree by or on behalf of the Indemnified
Party to the imposition upon it of any monetary or other liability or obligation which cannot
and/or will not be fully assumed and performed by the Indemnifying Party.

     10.5 Indemnification Obligations Survive Termination. The Parties’ indemnification
obligations under this Agreement shall survive termination or expiration of this Agreement.

ARTICLE 11 REPRESENTATIONS AND WARRANTIES

     11.1 Mylan warrants and represents the following:

          11.1.1 Mylan is a corporation duly organized, validly existing and in good standing under the
laws of the state of West Virginia.

          11.1.2 Mylan has all requisite power and authority to enter into this Agreement and has the
requisite skill, knowledge, staffing, financial resources and ability to carry out its obligations
hereunder. The person signing this Agreement has the necessary corporate authority to legally bind
Mylan to the terms set forth herein.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

11

 

          11.1.3 Mylan’s execution of this Agreement and performance of the terms set forth herein will
not cause Mylan to be in conflict with or constitute a breach of any agreement or understanding
with any Third Party.

          11.1.4 To Mylan’s knowledge and belief, there are no suits, actions, claims, proceedings, or
investigations pending or threatened by or before any court, by any governmental agency or any
person or entity relating to the matters set forth herein.

          11.1.5 Mylan’s execution of this Agreement and performance hereunder do not and will not be in
material conflict with any law, ordinance, statute or regulation.

          11.1.6 Mylan is not debarred and Mylan has not and will not knowingly use in any capacity the
services of any person debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement
Act of 1992.

          11.1.7 Mylan has and will maintain throughout the term of this Agreement all permits,
licenses, registrations and other forms of governmental authorization and approval as required by
applicable laws in order for Mylan to execute and deliver this Agreement and to perform its
obligations hereunder in accordance with all laws that are applicable to Mylan.

          11.1.8 [**]

          11.1.9 If at any time any of these representations and warranties is no longer accurate, Mylan
shall immediately notify DPSI of such fact.

     11.2 DPSI warrants and represents the following:

          11.2.1 DPSI is a corporation duly organized, validly existing and in good standing under the
laws of Delaware.

          11.2.2 DPSI has all requisite power and authority to enter into this Agreement and has the
requisite skill, knowledge, staffing, financial resources and ability to carry out its obligations
hereunder. The person signing this Agreement has the necessary corporate authority to legally bind
DPSI to the terms set forth herein.

          11.2.3 DPSI’s execution of this Agreement and performance of the teens set forth herein will
not cause DPSI to be in conflict with or constitute a breach of any agreement or understanding with
any Third Party.

          11.2.4 To DPSI’s knowledge and belief, there are no suits, actions, claims, proceedings, or
investigations pending or threatened by or before any court, by any governmental agency or any
person or entity relating to the Product or any other matters set forth herein.

          11.2.5 To DPSI’s knowledge and belief, the manufacture, use or sale of the Product in the
Territory does not and will not infringe upon the Dermik Patents.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

12

 

          11.2.6 [**]

          11.2.7 DPSI’s execution of this Agreement and performance hereunder do not and will not be in
material conflict with any law, ordinance, statute or regulation.

          11.2.8 DPSI is not debarred and DPSI has not and will not knowingly use in any capacity the
services of any person debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement
Act of 1992.

          11.2.9 DP SI has and will maintain throughout the term of this Agreement all permits,
licenses, registrations and other forms of governmental authorization and approval as required by
applicable laws in order for DPSI to execute and deliver this Agreement and to perform its
obligations hereunder in accordance with all laws that are applicable to DPSI.

          11.2.10 DPSI has not granted, and will not grant during the Term of this Agreement, any other
distribution rights to any Third Party or to any Affiliate of DPSI in the Territory regarding the
Product.

     11.3 Limitation of Representations and Warranties. Neither party shall be deemed to make any
representations or warranties, whether express or implied, except as specifically set forth herein.
All other warranties express or implied, including with regard to the Product to be supplied by
DPSI hereunder, and the implied warranties of merchantability and fitness for a particular purpose
are hereby disclaimed by each party.

ARTICLE 12 TERM AND TERMINATION

     12.1 Term. The Term of this Agreement shall commence on the date this Agreement is signed by
both Parties and shall continue until the tenth (10th) anniversary of the Commencement of
Commercial Sales of such Product in the Territory, unless earlier terminated in accordance with the
provisions of this Agreement (“Term of this Agreement”). The Term of this Agreement shall be
extended for a period equal to the period of judicial restraint if Product sales are enjoined and
the Product cannot lawfully be sold in the United States, notwithstanding the Parties’ expectation
that the Product does not infringe any Third Party intellectual property.

     12.2 Termination.

          12.2.1 This Agreement may be terminated by mutual agreement of the Parties, or by either Party
upon sixty (60) days’ prior written notice to the other Party if such other Party breaches any
material provision of this Agreement and fails to cure that breach within such sixty (60) day
period. Any notice of material breach under this Section shall specify the default complained of,
setting forth the underlying reasons for its belief a default has occurred and the remedy sought.
The Party allegedly in default may cure the asserted breach or pursue the dispute resolution and
arbitration process specified in Section 13.8 within the notice period. If arbitration is demanded
the Agreement shall continue in full force and effect as if the alleged breach had not occurred,
pending the outcome of such arbitration.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

13

 

          12.2.2 Either party may terminate this Agreement on immediate notice if at any time the other
Party: (a) voluntarily files in any court pursuant to any statute of any governmental authority a
petition in bankruptcy or insolvency or for the appointment of a receiver or trustee of such party
or of its assets; (b) shall be served with an involuntary petition against it, filed in any
insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the
filing thereof; (c) shall be a party to any dissolution or liquidation; or (d) makes a general
assignment for the benefit of creditors.

          12.2.3 This Agreement may be terminated on immediate notice if the manufacture, distribution
or sale of the Product in the Territory would materially contravene any applicable Law; provided,
however, no termination shall occur if the manufacture, distribution or sale of the Product can be
brought into compliance with such Law within a reasonable period of time and at a reasonable
expense to the parties hereto following the notice of non-compliance or violation.

          12.2.4 Termination of this Agreement for any reason shall be without prejudice to: (a) DPSI’ s
right to receive all payments due from Mylan, if any, as of the effective date of such termination;
(b) Mylan’s right to receive all payments due from DPSI, if any, as of the effective date of such
termination; (c) Mylan’s right to sell such Product remaining in its inventory, and at Mylan’s
option, Mylan may elect to take delivery of and sell the Product covered by any purchase order
issued by Mylan prior to the effective date of termination; and (d) any other legal, equitable, or
administrative remedies as to which either Party is or may become entitled.

ARTICLE 13 MISCELLANEOUS PROVISIONS

     13.1 Governing Law. This Agreement shall by governed by the laws of the state of New York.

     13.2 Confidentiality. The existence of this Agreement and its terms, and all communications
between the Parties and their representatives relating to the subject matters of this Agreement
shall be considered Confidential Information under the Confidentiality Agreement between Mylan and
DPSI dated November 8, 2006 and as amended October 30, 2007, and shall not be disclosed by either
Party except as authorized by such Confidentiality Agreement (as amended) or as required by law.
Notwithstanding anything in this Section 13.2 or the Confidentiality Agreement to the contrary,
DPSI may disclose this Agreement and its terms to (i) any potential acquiror of all of the equity
of DPSI, (ii) any potential purchaser of all or substantially all of the assets of DPSI or (iii)
any underwriter for the public offering of the equity securities of DPSI, in each case subject to
the prior execution by such potential acquiror, purchaser or underwriter of a confidentiality
agreement that is no less restrictive in terms and scope than the provisions of the Confidentiality
Agreement with respect to the Confidential Information. All confidential communications between
the Parties pertaining to legal matters shall be conducted subject to a common interest privilege
agreement between the Parties.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

14

 

     13.3 Licenses and Permits. Each Party shall, at its sole cost and expense, maintain in full
force and effect all necessary licenses, permits, and other authorizations required by law in order
to carry out its duties and obligations hereunder.

     13.4 Independent Contractors. This Agreement shall not constitute or give rise to any
employer-employee, agency, partnership, or joint venture relationship among or between the Parties,
and each Party’s performance hereunder is that of a separate, independent entity in pursuit of a
common purpose.

     13.5 No Modification. None of the terms of this Agreement shall be amended or modified except
in writing signed by all the Parties.

     13.6 Successors and Assigns. Any change of control of Mylan, whether by the sale of
substantially all of Mylan assets or a majority of Mylan’s shares, to a Third Party shall give rise
to the right of DPSI to terminate this Agreement with immediate effect and reclaim all rights
regarding the Product in the Territory. DPSI shall have thirty (30) days from the date of receipt
of notice from Mylan that a change of control of Mylan has occurred to exercise this right. Except
for an assignment to an Affiliate of a Party, neither Party shall assign any of its rights or
obligations under this Agreement without the prior written consent of the other Party, such consent
may be withheld on the grounds of reasonable and articulated commercial considerations. Subject to
the foregoing, each Party shall be entitled to assign all or any of its rights or obligations under
this Agreement to an Affiliate.

     13.7 Entire Agreement. This Agreement constitutes the entire agreement between the Parties
respecting the subject matter hereof and supersedes all previous term sheets, correspondence and
any and all other writings and understandings except for the Confidentiality Agreement, as amended,
as referred to in Section 13.2 which shall remain in full force and effect.

     13.8 Dispute Resolution / Arbitration. All disputes between the Parties relating to or
arising out of this Agreement, including but not limited to disputes, claims, defenses involving or
requiring the interpretation, validity, enforceability, alleged breach or performance of this
Agreement, shall be subject to the following dispute resolution procedure.

     First, the dispute shall be presented to the President of Mylan and the Chief Executive
Officer of DPSI. If the President and CEO are unable to resolve the dispute in a mutually
satisfactory manner then the matter shall be submitted to a non-binding mediation before a mediator
chosen by, and acceptable to, both Parties.

     If the Parties cannot resolve their dispute through non-binding mediation, then the matter
shall be finally resolved by arbitration under the rules of the American Arbitration Association
regarding commercial disputes. The arbitration proceedings shall be conducted in New York City,
New York, or in such other location as the Parties may mutually agree. The Parties will each bear
their own costs and expenses, including legal fees, incurred in connection with such arbitration
proceedings.

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

15

 

     Nothing in this Section 13.8 restricts either Party’s freedom to seek urgent relief from a
court to preserve a legal right or remedy, or to protect a proprietary or trade secret right, or to
otherwise seek emergency legal or equitable remedies necessary to preserve or restore the status
quo pending the outcome of arbitration, and no such court action shall be deemed a waiver of the
requirement to arbitrate disputes pursuant to this Section.

     13.9 Limitation of Liability. In no event shall either Party or their respective Affiliates
be liable to the other Party or its Affiliates for special, punitive, indirect, incidental,
exemplary or consequential loss or damage, or for lost profits, based on a contract, tort, or any
other legal theory, arising out any breach of this Agreement or otherwise relating to the subject
matter of this Agreement, except as may be specifically and expressly stated in this Agreement.

     13.10 Severability. To the extent any provision or term of this Agreement is or becomes
unenforceable or invalid by operation of Law, such unenforceability or invalidity shall not affect
the remaining provisions of this Agreement. The Parties agree to renegotiate in good faith a
substitute provision that to the extent possible accomplishes the original business purpose of the
provision held to be unenforceable or invalid.

     13.11 Construction. The language in all parts of this Agreement shall be construed, in all
cases, according to its plain meaning. The Parties acknowledge that each Party and its legal
counsel have reviewed this Agreement and that any rule of construction to the effect that any
ambiguities are to be resolved against the drafting Party shall not be employed in the
interpretation of this Agreement. The Article and Section headings and captions are placed herein
merely as a matter of convenience and shall not affect the construction or interpretation of any of
the provisions of this Agreement.

     13.12 No Third Party Benefit. This Agreement shall be binding upon and inure solely to the
benefit of the Parties, their respective Affiliates and their permitted assigns, and nothing in
this Agreement, express or implied, is intended to or shall confer upon any Third Party any right,
benefits or remedies of any nature whatsoever under or by reason of this Agreement.

     13.13 Further Acts. Each of the Parties shall do, execute and perform and shall procure to be
done and perform all such further acts, deeds, documents and things as the other Party may
reasonably require from time to time to give full effect to the terms of this Agreement.

     13.14 Press Releases. All press releases and other public announcements relating to this
Agreement or the transactions contemplated hereby will be prepared and issued only with the prior
mutual consent of Mylan and DPSI, except that Mylan may disclose freely that DPSI is the inventor
of the Product, and otherwise except as disclosure may be required by Law.

     13.15 Costs. Each Party will pay its own costs and expenses in connection with the
negotiation, preparation, execution and performance of this Agreement, except as otherwise provided
herein.

     13.16 Notices. Any notices given under this Agreement shall be in writing, sent by overnight
delivery by a reputable service (e.g. FedEx) with an additional copy by fax or e-mail,

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

16

 

and shall be deemed effective on the date of mailing. Unless otherwise changed by notice in
writing, notices may be served at the following addresses:

	 	 	 
	If to Mylan:

	 	If to DPSI:
	 
	 	 
	Mylan Pharmaceuticals Inc.

	 	Dow Pharmaceutical Sciences, Inc.
	781 Chestnut Ridge Road

	 	1330 Redwood Way
	Morgantown, WV 26505

	 	Petaluma, CA 94954-1169
	Attn: President

	 	Attn: President and CEO
	 
	 	 
	With a copy to:
	 	 
	 
	 	 
	Mylan Inc.
	 	 
	1500 Corporate Drive, Suite 400
	 	 
	Canonsburg, PA 15317
	 	 
	Attn: General Counsel
	 	 

     13.17 Counterparts. This Agreement may be executed in one or more counterparts, each of which
is to be considered an original and taken together as one and the same document. Faxed or
electronic images of signatures shall be effective as an original.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	EXECUTED AND AGREED:	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	DOW PHARMACEUTICAL SCIENCES, INC.	 	 	 	MYLAN PHARMACEUTICALS INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Bhaskar Chaudhuri	 	 	 	By:	 	/s/ Harry A. Korman	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Printed Name:
	 	Bhaskar Chaudhuri
	 	 	 	 	 	Printed Name:
	 	Harry A. Korman	 	 
	 

	 	Title:
	 	President and CEO
	 	 	 	 	 	Title:
	 	President North America	 	 
	 

	 	Date:
	 	3-14-2008
	 	 	 	 	 	Date:
	 	3-12-2008	 	 

 

			
	**	 	CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]